Inspire treatment—a hypoglossal nerve stimulation device—has been FDA-cleared for over 11 years, with more than 100,000 patients assisted throughout the US, Europe, and Asia. Ruchir Patel, Inspire’s senior medical director, states evidence indicates decreases in daytime somnolence, a 79 percent decline in sleep apnea intensity, and a 90 percent reduction in snoring. Early US data reveal average nightly application of greater than 6.5 hours. “This is a promising era because more therapeutic options are accessible than previously,” he remarks. Related: The Year-Long Grow-Off: U…
Drug-based solutions are also surfacing. In 2024, the US Food and Drug Administration sanctioned Zepbound (tirzepatide) for mid to acute OSA in obese adults—the first weight-loss medication to bear a specific sleep apnea designation. Related: Hofstra Shatters 25-Year …
Concurrently, Cambridge, Massachusetts–based new venture Apnimed has created a nightly pill aiming at neuromuscular pathways that affect upper airway tone. Rather than physically propping the airway open, the medication seeks to biologically firm it.
“For an extended period, OSA was perceived mainly as a structural issue, so the apparent remedy was physical,” says John Cronin, chief medical officer at Apnimed. As comprehension advanced, the question became: “Could we devise a therapy that directly addresses the biology of the condition, rather than depending exclusively on mechanical support?” The company has finalized two phase three trials and intends to present a New Drug Application to the FDA this year.
Despite all the advancements, Steier maintains a practical outlook. “I couldn’t be more content than finding someone who’s got standard sleep apnea and receives CPAP therapy,” he shares. Contemporary devices autonomously regulate pressure to respiratory tract impedance. “A single night can transform the situation.” Patients return revitalized, telling him they’ve reclaimed their vitality.
Sleep medicine is still comparatively nascent, and research is just commencing to grasp the variability of the condition. That intricacy also forms the basis of endeavors to enhance CPAP use rather than forsake it.
Amanda Sathyapala, a senior lecturer at Imperial College London’s National Heart and Lung Institute, headed the study revealing 62 percent of patients were insufficiently utilizing CPAP to achieve a significant health benefit. Her team has investigated the behavioral aspects of compliance, discovering that elements such as comprehending dangers and self-assurance with the apparatus influence long-term use.
Leveraging behavioral science, she created CPAP Buddy, an app providing video-based behavioral guidance, mutual assistance, and 24/7 responses to patient questions. The project has secured £2.2 million from the UK’s Medical Research Council, with additional support from CPAP producer Fisher & Paykel.
“CPAP is probably the most potent therapy that you can get because it’s delivering air straight into the airway,” Sathyapala states. “[CPAP] is consistently going to be the most successful when individuals apply it, therefore it merits effort to get people to use it.”
For her, the challenge is not the device but conduct. “I don’t like to relinquish if we haven’t attempted appropriate measures,” she says. Utilizing CPAP, she adds, is akin to “losing weight, quitting tobacco, initiating a long-term exercise regimen—it’s a modification in habits.”
{content}
Source: {feed_title}